US FTC Removing ‘Handcuffs’ To Pursue Pharma Companies, PBMs For Antitrust Violations
Agency staff has more freedom to launch investigations under resolutions approved at Commission’s first meeting under new chair. Mergers and rebate walls expected to be major priorities.
You may also be interested in...
Congressional Republicans and biopharma stakeholders support legislation clarifying the Federal Trade Commission’s authority to assess monetary penalties but argue the House legislation needs guardrails.
Legislation to prevent pay-for-delay deals, product hopping and sham citizen petitions, and to require the FTC to study the role of pharmacy benefit managers in the drug supply chain get unanimous committee vote. They may have a good shot at passage given recent actions by President Biden and the FTC, and bipartisan interest in drug pricing.
They may have a good shot at passage given recent actions by President Biden and the Federal Trade Commission, and bipartisan interest in drug pricing.